
GHRS Stock Forecast & Price Target
GHRS Analyst Ratings
Bulls say
GH Research is a clinical-stage biopharmaceutical company focused on developing a practice-changing treatment for depression, with a primary focus on patients with Treatment-Resistant Depression (TRD). They currently have two product candidates in their portfolio, GH001 and GH002, both of which are in clinical trials. The company's balance sheet strengthened in the first quarter of 2026, and they raised an additional $111.2 million in net proceeds through an underwritten offering in April, providing them with pro forma liquidity of approximately $378.5 million. Phase 2b data for GH001 was published in a peer-reviewed journal, providing validation for the product's potential, and the company has made significant progress in Phase 3-enabling work, including completing enrollment in a Phase 1 trial and selecting doses for the global Phase 3 pivotal program. GH Research also has strong intellectual property protections in place, with multiple patents pending for novel uses and compositions of their product candidates. While the biotech industry can be complex and competitive, GH Research's differentiated profile, including its proprietary aerosol delivery device and 11-minute median psychoactive duration, and recent positive data and operational updates indicate that they are on track to move their product candidates forward towards regulatory approval.
Bears say
GH Research is heavily focused on the development of its lead product, GH001, a inhalable form of the psychoactive drug 5-MeO-DMT, and has deferred its preparations for Phase 1 trials for its other product, GH002, suggesting a lack of confidence in its success. Additionally, although the company has generated buzz within the psychiatry community, there is a lack of concrete evidence to support widespread commercial adoption. The company's financials may appear strong, with $267M in cash and a reported earnings increase, but its plans for outer-year adoption are based on assumptions and do not accurately reflect the uncertain nature of the psychiatric field.
This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.
GHRS Analyst Forecast & Price Prediction
Start investing in GHRS
Order type
Buy in
Order amount
Est. shares
0 shares